Blue Horseshoe Stocks: CNET Recap & More

ChinaNet Online Holdings, Inc. CNET

CNET made an excellent move following its inclusion in yesterday’s morning report, as the stock would go on to trade in an impressive range fromĀ  a low of 2.41 up to a new annual high of 3.98 on nearly 34x its one-month average volume. The strong 65% intraday run came in the first hour of trading, so folks had the chance at some very rapid, very substantial gains. Congrats if you were among them!


Direxion Daily Jr Gld Mnrs Bear 3X ETF (JDST)

We introduced JDST as a way to leverage against the falling prices of gold yesterday, and it’s working out in our favor so far. This ETF didn’t waste any time Monday morning, as it began a morning ascent that would last all day and carry it from a low of 14.65 to 16.88, a modest yet solid gain of 15%

We’ll have our eyes on this one for as long as it appears that the dollar will continue to strengthen.


OTHER ITEMS OF INTEREST

Our scanner yielded three interesting plays with news out of varying subjects.

NXT-ID, Inc. NXTD, has a mobile wallet product that they bill as the truly the first universal secure payment solution, which, as it does not require a smart-phone, provides certain advantages over other eWallet-type products now being pushed by Apple (ApplePay) among others. The stock made a significant move in yesterday’s trading, and will be on our radars today. >>> Shareholder Update PR

China Jo-Jo Drugstores, Inc. CJJDreleased financials yesterday and received a warm reception from traders. Some of the highlights included:

  • Online sales contributed $2.6 million in revenue, an increase of 103.5% from the comparable quarter of prior year
  • Retail sales, which includes online sales, accounted for approximately 80.0% of total revenue, and increased by $2.3 million, or 20.7% year over year to $13.2 million
  • Wholesale, which accounted for approximately 20.0% of total revenue, decreased to $3.3 million from $4.4 million for the same quarter of last year. >>> VIEW FULL PR

Synthetic Biologics, Inc. SYN Earlier last wee the FDA granted orphan drug status to SYN’s monoclonal antibody (mAb) combination, “SYN-005”. After a period of consolidation off of the initial run that produced, the stock is gapping up in the premarket today, so we’ll definitely want to keep an eye peeled.


Extended Watchlist:
OTIV, NETE, NVAX, USAT